Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian CancerPRNewsWire • 07/21/25
Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific ConferencesPRNewsWire • 06/12/25
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare ConferencePRNewsWire • 03/03/25
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing TechnologyPRNewsWire • 02/26/25
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025PRNewsWire • 02/18/25
Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferencePRNewsWire • 02/04/25
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid TumorsPRNewsWire • 01/08/25
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG AntibodiesPRNewsWire • 11/27/24
Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024PRNewsWire • 11/05/24
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024PRNewsWire • 10/29/24